• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Bronchodilators do not improve symptomatic tobacco-exposure in patients with preserved lung function

byNhat Hung (Benjamin) LamandKiera Liblik
October 17, 2022
in Chronic Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Inhaled dual bronchodilator therapy did not reduce respiratory symptom points in tobacco-exposed persons with preserved lung function. 

2. Compared to placebo, there was no difference in lung function measures in those treated with bronchodilators.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Tobacco smoke is an established cause of chronic obstructive pulmonary disease (COPD), resulting in reduced forced expiratory volume in 1 second (FEV1) relative to forced vital capacity (FVC) not reversible by bronchodilators. Some tobacco-exposed individuals whose lung function is preserved as measured by spirometry also exhibit respiratory symptoms similar to those with COPD. Although it has been found that airway-wall thickening and mucus concentration may contribute to these symptoms, independent from lung function, it remains unclear if bronchodilators are beneficial in this patient population. The current study was a multicenter randomized controlled trial to determine if a dual therapy of long-acting β2-agonist indacaterol and long-acting muscarinic antagonist glycopyrrolate could improve respiratory symptoms in tobacco-exposed individuals with preserved lung function. At 12 weeks, no significant differences were observed in the St. George’s Respiratory Questionnaire (SGRQ) symptom assessment score, FEV1, and inspiratory capacity between the treatment and the placebo group. The study limitations included a limited follow-up period and dose limits as approved by the Food and Drug Adminstration. Nevertheless, these results showed that for tobacco-exposed patients with preserved lung function, the current dual bronchodilator regimen did not result in the abatement of their respiratory symptoms.

Click here to read the study in NEJM

In-Depth [randomized controlled trial]: The current study was a multicenter randomized controlled trial that assessed the efficacy of dual long-acting bronchodilator therapy in treating tobacco-exposed patients with preserved lung function. Persons between 40 and 80 years of age who currently or previously smoked cigarettes with at least a 10-pack-year history, had respiratory symptoms as defined by the COPD Assessment Test score of at least 10, and preserved lung function as measured by spirometry were included. Exclusion criteria included asthma, other concomitant lung disease, and the current use of combination maintenance therapy. In the modified intention-to-treat analysis, 471 participants were randomized 1:1 to receive either indacaterol 27.5µg combined with glycopyrrolate 15.6µg or a placebo for 12 weeks. The primary outcome was an improvement by at least four points in the SGRQ score without treatment failure, which is defined as an increase in lower respiratory symptoms necessitating treatment with a long-acting bronchodilator, glucocorticoid, or antibiotic. Overall, at 12 weeks, 128 of 227 participants (56.4%) in the treatment group and 144 of 244 (59.0%) in the placebo group achieved the primary outcome (difference, -2.6 percentage points; 95% confidence interval [CI], -11.6 to 6.3; adjusted odds ratio, 0.91; 95% CI, 0.60 to 1.37; p=0.65). The mean change from baseline in the FEV1 was 0.04L (95% CI, 0.01 to 0.08) in the treatment group and -0.01L (95% CI, -0.04 to 0.02) in the placebo group, while the mean change in inspiratory capacity was 0.12L (95% CI, 0.07 to 0.18) in the treatment group and 0.02L (95% CI, -0.03 to 0.08). Treatment failure was uncommon in both groups. Despite the limited follow-up period, these results showed that dual bronchodilator therapy did not relieve respiratory symptoms in tobacco-exposed patients with preserved lung function.

Image: PD

RELATED REPORTS

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis

Efanesoctocog alfa is efficacious in treating severe hemophilia A

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bronchodilatorchronic diseasecigarette smokeindacaterolinternal medicinepulmonary functionpulmonologysmoking
Previous Post

Polycystic ovarian syndrome is associated with an increased risk of pancreatic cancer

Next Post

Beneficial effect of intensive blood pressure control on cardiovascular and all-cause mortality not persist after trial intervention – a secondary analysis of the SPRINT trial

RelatedReports

Intravenous contrast may not increase risk of acute kidney injury
Chronic Disease

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

February 3, 2023
Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis

February 3, 2023
Nonleg venous thromboses associated with PE, longer ICU stay
Chronic Disease

Efanesoctocog alfa is efficacious in treating severe hemophilia A

February 2, 2023
Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Next Post
Prevalence of hypertension among adolescents varies by race and BMI

Beneficial effect of intensive blood pressure control on cardiovascular and all-cause mortality not persist after trial intervention – a secondary analysis of the SPRINT trial

Shorter time to angioplasty may improve heart attack outcomes

Percutaneous coronary intervention inefficacious in improving severe ischemic left ventricular dysfunction

Cervical length at term helps predict delivery date

Identification of risk factors for incident cervical insufficiency in nulliparous and parous women

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options